Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vicore Pharma Holding AB (publ) (VICO.ST)
SEK11.60
-0.16 (-1.36%)
SE STO Healthcare Biotechnology
Address
Kronhusgatan 11 411 05
Stockholm, SE
Stockholm, SE
CEO
Ahmed S. Mousa
Website
vicorepharma.com
IPO
2015-12-10
ISIN SE0007577895
Description
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK11.60
-0.16 (-1.36%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
601.3K
Beta
0.18
Float Shares
182.05M
Free Float %
76.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.18% | +7.02% | +13.03% | +6.02% | +8.67% | +2.73% | +39.78% | -52.68% | -49.26% | +82.52% | +86.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11.60
DCF (Unlevered)
2.44
-79.0%
DCF (Levered)
2.44
-79.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
18.82
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-96.5% Q1'26: -32.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-165.3% Q1'26: +18.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,314.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-11,905.8% Q1'26: -20,515.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +716.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.5% Q1'26: +20.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
852.0K
est: 704.0K (+21.0%)
|
932.0K
est: 1.20M (-22.3%)
|
508.0K
est: 3.31M (-84.6%)
|
—
est: 22.0K (-100.0%)
|
—
est: 27.60M (-100.0%)
|
—
est: 104.24M (-100.0%)
|
109.35M
est: 103.74M (+5.4%)
|
3.82M
est: 2.63M (+44.9%)
|
6.93M
6.93M – 6.93M
+163.2% YoY
|
31.68M
31.68M – 31.68M
+357.0% YoY
|
102.94M
102.94M – 102.94M
+225.0% YoY
|
3.82M
3.82M – 3.82M
-96.3% YoY
|
3.82M
3.82M – 3.82M
+0.0% YoY
|
| EBITDA |
-6.65M
est: 422.4K (-1,673.4%)
|
-23.81M
est: 720.0K (-3,407.5%)
|
-38.25M
est: 1.98M (-2,027.0%)
|
-92.51M
est: 13.2K (-700,956.1%)
|
-286.20M
est: 16.56M (-1,828.4%)
|
-317.47M
est: 20.85M (-1,622.7%)
|
-166.64M
est: 20.75M (-903.2%)
|
-454.45M
est: 526.7K (-86,387.1%)
|
1.39M
1.39M – 1.39M
+163.2% YoY
|
6.34M
6.34M – 6.34M
+357.0% YoY
|
20.59M
20.59M – 20.59M
+225.0% YoY
|
763.4K
763.4K – 763.4K
-96.3% YoY
|
763.4K
763.4K – 763.4K
+0.0% YoY
|
| EBIT |
-6.65M
est: 422.4K (-1,674.8%)
|
-24.17M
est: 720.0K (-3,456.8%)
|
-21.33M
est: 1.98M (-1,174.6%)
|
-93.92M
est: 13.2K (-711,637.9%)
|
-288.80M
est: 16.56M (-1,844.1%)
|
-320.89M
est: 20.85M (-1,639.1%)
|
-168.88M
est: 20.75M (-914.0%)
|
-454.45M
est: 526.7K (-86,387.1%)
|
1.39M
1.39M – 1.39M
+163.2% YoY
|
6.34M
6.34M – 6.34M
+357.0% YoY
|
20.59M
20.59M – 20.59M
+225.0% YoY
|
763.4K
763.4K – 763.4K
-96.3% YoY
|
763.4K
763.4K – 763.4K
+0.0% YoY
|
| Net Income |
-6.65M
est: -88.52M (+92.5%)
|
-12.86M
est: -97.18M (+86.8%)
|
-21.68M
est: -30.69M (+29.4%)
|
-93.08M
est: -452.59M (+79.4%)
|
-288.42M
est: -819.77M (+64.8%)
|
-310.94M
est: -432.02M (+28.0%)
|
-168.63M
est: -195.74M (+13.8%)
|
-477.47M
est: -428.62M (-11.4%)
|
-422.10M
-466.72M – -377.49M
+1.5% YoY
|
-411.80M
-462.15M – -185.60M
+2.4% YoY
|
-327.44M
-410.20M – -244.68M
+20.5% YoY
|
-394.61M
-394.61M – -394.61M
-20.5% YoY
|
-405.40M
-405.40M – -405.40M
-2.7% YoY
|
| SGA |
5.01M
est: 628.2K (+696.9%)
|
5.43M
est: 1.07M (+407.2%)
|
8.62M
est: 2.95M (+192.2%)
|
26.88M
est: 19.6K (+136,814.8%)
|
37.53M
est: 24.62M (+52.4%)
|
44.60M
est: 443.11M (-89.9%)
|
50.44M
est: 440.96M (-88.6%)
|
67.91M
est: 11.19M (+506.7%)
|
29.46M
29.46M – 29.46M
+163.2% YoY
|
134.65M
134.65M – 134.65M
+357.0% YoY
|
437.57M
437.57M – 437.57M
+225.0% YoY
|
16.23M
16.23M – 16.23M
-96.3% YoY
|
16.23M
16.23M – 16.23M
+0.0% YoY
|
| EPS |
-0.47
est: -0.39 (-19.6%)
|
-0.76
est: -0.43 (-76.2%)
|
-0.95
est: -0.14 (-597.4%)
|
-2.16
est: -2.01 (-7.5%)
|
-3.99
est: -3.64 (-9.7%)
|
-3.22
est: -1.80 (-78.8%)
|
-0.75
est: -0.82 (+8.1%)
|
-1.99
est: -1.79 (-11.4%)
|
-1.81
-1.95 – -1.57
-1.4% YoY
|
-1.40
-1.93 – -0.77
+23.0% YoY
|
-1.34
-1.71 – -1.02
+4.2% YoY
|
-1.65
-1.65 – -1.65
-23.1% YoY
|
-1.69
-1.69 – -1.69
-2.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-192.98M
OE per share TTM
-0.82
Owner's Yield
-6.50%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 20.4K | 0.07% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 6.5K | 0.30% |
| 3 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 298.7K | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-137.7K
Shares Outstanding
238.56M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ahmed S. Mousa | Chief Executive Officer | 8M | male |
| Anne-Katrine Cohrt | Head of Clinical Operations | — | female |
| Bertil Lindmark | Chief Medical Officer | — | — |
| Hans Jeppsson | Chief Financial Officer | — | male |
| Helen Barker | Chief Technology Officer | — | female |
| Jimmie Hofman | Chief Business Officer | — | male |
| Johan Raud | Chief Scientific Officer | — | — |
| Johanna Grans | Head of Non-Clinical Development | — | female |
| Lene Eskildsen | Head of Quality Assurance | — | female |
| Megan Richards | Vice President of Investor Relations, Communications & Portfolio Strategy | — | female |
| Mikael Nygård | Chief Operating Officer | — | male |
| Nina Carlen | Chief Administrative Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VICO.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
